

Online Supplementary Material

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece. *JHEOR*. 2022;9(1):50-57. [doi:10.36469/jheor.2022.32983](https://doi.org/10.36469/jheor.2022.32983)

Table S1: Frequencies of Adverse Events Considered in the Model

Table S2: Monitoring Cost in Pre- and Post-progression State

Table S3: Adverse Event Management Cost Considered in the Model

This supplementary material has been provided by the authors to give readers additional information about their work.



Table S1: Frequencies of Adverse Events Considered in the Model

Adverse Event	Lorlatinib ^a	P-ChT ^b
Increased alanine aminotransferase	0%	1.4%
Increased aspartate aminotransferase	0.4%	0.7%
Diarrhea	0.4%	0.7%
Fatigue	0.4%	0%
Hypercholesterolemia	15.6%	0%
Hypertriglyceridemia	15.6%	0%
Nausea	0%	2%
Anemia	0%	1.4%
Neutropenia	0%	14.3%

Abbreviation: P-ChT, pemetrexed plus carboplatin or cisplatin.

^a Source: Solomon et al.¹⁴

^b Sources: Novello et al⁷; Shaw et al.²⁰

Table S2: Monitoring Cost in Pre- and Post-progression State

Resource Item	Cost/Test (€)	% of Patients	No. of Tests/ Month
Health professional visit			
Oncologist	10.00	80	1
Laboratory tests			
Complete blood count	1.69	80	2
Chest x-ray	3.44	30	1
Biochemical analysis	22.07	80	2
CT scan (chest)	38.25	30	1
Total cost per cycle in pre- and post-progression			€57.69

Table S3: Adverse Event Management Cost Considered in the Model

Adverse Event	Unit Cost/ Event (€)	Source
Increased alanine aminotransferase	141.66	
Increased aspartate aminotransferase	145.60	
Diarrhea	73.58	DRGs tariffs, ²⁶ EOPYY
Fatigue	46.44	website, ²⁵ government gazette
Hypercholesterolemia	79.98	(Law, B'1181/8 May 2014),
Hypertriglyceridemia	77.95	and the drug price bulletin ²³
Nausea	57.63	
Anemia	833.83	
Neutropenia	527.63	

Abbreviation: DRG, Diagnostic Related Group.